Accredited Educational Activities

A Close Look at the Diagnosis and Treatment of Patients with Retinal Vascular Disease

This online activity targets healthcare gaps related to the diagnosis and management of diabetic retinopathy (DR), age-related macular degeneration (AMD), and retinal vein occlusion (RVO), impacting outcomes through risk stratification, diagnostic strategies, and treatment individualization with anti-VEGF agents.

CLICK ON STATES TO SEE LIVE ACTIVITIES

BOOTH TOUR

Jun
21
Sun
Seeing Past the Treatment Horizon: Anti-VEGF Therapies and Beyond in Retinal Disease Track: Age-related Macular Degeneration (Optometry)
Jun 21 2020 @ 9:00 am – Oct 1 2022 @ 10:00 am

Seeing Past the Treatment Horizon: Anti-VEGF Therapies and Beyond in Retinal Disease Track: Age-related Macular Degeneration (Optometry)

View Activity

FACULTY

Steven Ferrucci, OD, FAAO
Chief of Optometry, Sepulveda VA Medical Center
Los Angeles, CA
Professor, Southern California College of Optometry at Marshall B. Ketchum University
Fullerton, CA

PROGRAM OVERVIEW

This online activity targets healthcare gaps related to evidence-based recognition and prevention as well as timely treatment and management of age-related macular degeneration (AMD), impacting visual outcomes through guidelines and best practices, clinical trial data and strategies to facilitate earlier initiation of therapy.

  • By addressing these gaps, you can assess whether your approach to AMD management through utilization of current treatment guidelines, individualization of treatment approach and strategies for overcoming treatment barriers – could be modified to help close these gaps.
  • Expert discussion will guide you in analyzing and identifying appropriate candidates for anti-VEGF therapy, utilizing guidelines and clinical trial data on efficacy and safety to affect patient outcomes.
  • You will also be immersed in dynamic animations utilizing a virtual reality platform to memorably highlight key points related to anti-VEGF therapy in AMD and the recognition of retinal vasculitis.

TARGET AUDIENCE

This activity is designed to meet the educational needs of retina specialists, ophthalmologists, primary care providers, optometrists, and other healthcare providers who manage patients with age-related macular degeneration.

LEARNING OBJECTIVES

After completing the CME activity, learners should be better able to:

  • Incorporate consistent use of evidence-based screening and prevention strategies for patients at risk of AMD
  • Apply clinical trial data and guidelines to the selection of therapies for the treatment of patients with AMD
  • Identify barriers to early intervention and communicate to patients the importance for early initiation of therapy in AMD

ACCREDITATION STATEMENT: Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.

CREDIT DESIGNATION STATEMENT: Med Learning Group designates this online activity for a maximum of 1.25 AMA Category 1 creditTM. Physicians should claim only the credit commensurate with the extent of their participation in the live virtual activity.

NURSING CREDIT INFORMATION: Purpose: This program would be beneficial for nurses involved in the care of patients with AMD. Credits: 1.25 ANCC Contact Hour.

CNE Accreditation Statement:

Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 1.25 contact hour of continuing nursing education of RNs and APNs.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG‐sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Steven Ferrucc, OD, FAAO discloses the following financial interests or relationships:

  • Consultant: Centervue, Science Based Health, Visible Genomics
  • Speakers’ Bureau: Genentech, MacuLogix, Regeneron, Notal Vision

CME Content Review

The content of this activity was independently peer-reviewed. The reviewer of this activity has nothing to disclose.

CNE Content Review

The content of this activity was peer-reviewed by a nurse reviewer.

Teresa L. Keating, MSN, RN, WHNP
Ultimate Medical Academy/CCM – Lead Nurse Planner

The reviewer of this activity has nothing to disclose

Staff Planners and Managers

The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

  • Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to d
  • Christina Gallo, SVP, Educational Development of Med Learning Group, has nothing to
  • Chris Drury, Director of Medical and Scientific Services of Med Learning Group, has nothing to disclose.
  • Teresa L. Keating, MSN, RN, WHNP, UMA/CMM – LNP, has nothing to disclose.
  • Ana Maria Albino, Senior Program Manager of Med Learning Group, has nothing to
  • Amanda Jenkins, Program Coordinator of Med Learning Group, has nothing to disclose.
  • Brianna Hanson, MPH, Outcomes and Accreditation Coordinator of Med Learning Group, has nothing to disclose.
  • Lauren Welch, MA, VP, Accreditation and Outcomes of Med Learning Group, has nothing to

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During the course of this lecture, the faculty may mention the use of medications for both FDA‐approved and non‐approved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this online activity. To receive CME/CNE credit participants must:

  1. Read the CME/CNE information and faculty disclosures;
  2. Participate in the online activity; and
  3. Complete pre-and-post surveys and evaluations.

You will receive your certificate as a downloadable file.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision‐making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at [email protected]

RELEASE DATE: October 01, 2021

EXPIRATION DATE: October 01, 2022

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy‐policy/

Copyright © 2021 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form other than personal use without the express written permission of Med Learning Group is prohibited.

View Activity

Jun
22
Mon
Seeing Past the Treatment Horizon: Anti-VEGF Therapies and Beyond in Retinal Disease Track: Age-related Macular Degeneration (Retina/Ophthalmology)
Jun 22 2020 @ 9:00 am – Oct 1 2022 @ 10:00 am

Seeing Past the Treatment Horizon: Anti-VEGF Therapies and Beyond in Retinal Disease Track: Age-related Macular Degeneration (Retina/Ophthalmology)

View Activity

FACULTY

SriniVas Sadda, MD
Professor of Ophthalmology
Doheny Eye Institute
David Geffen School of Medicine
University of California – Los Angeles

PROGRAM OVERVIEW

This online activity targets healthcare gaps related to evidence-based recognition and prevention as well as timely treatment and management of age-related macular degeneration (AMD), impacting visual outcomes through guidelines and best practices, clinical trial data and strategies to facilitate earlier initiation of therapy.

  • By addressing these gaps, you can assess whether your approach to AMD management through utilization of current treatment guidelines, individualization of treatment approach and strategies for overcoming treatment barriers – could be modified to help close these gaps.
  • Expert discussion will guide you in analyzing and identifying appropriate candidates for anti-VEGF therapy, utilizing guidelines and clinical trial data on efficacy and safety to affect patient outcomes.
  • You will also be immersed in dynamic animations utilizing a virtual reality platform to memorably highlight key points related to anti-VEGF therapy in AMD and the recognition of retinal vasculitis.

TARGET AUDIENCE

This activity is designed to meet the educational needs of retina specialists, ophthalmologists, primary care providers, optometrists, and other healthcare providers who manage patients with age-related macular degeneration.

LEARNING OBJECTIVES

After completing the CME activity, learners should be better able to:

  • Incorporate consistent use of evidence-based screening and prevention strategies for patients at risk of AMD
  • Apply clinical trial data and guidelines to the selection of therapies for the treatment of patients with AMD
  • Identify barriers to early intervention and communicate to patients the importance for early initiation of therapy in AMD

ACCREDITATION STATEMENT: Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.

CREDIT DESIGNATION STATEMENT: Med Learning Group designates this online activity for a maximum of 1.0 AMA Category 1 creditTM. Physicians should claim only the credit commensurate with the extent of their participation in the live virtual activity.

NURSING CREDIT INFORMATION: Purpose: This program would be beneficial for nurses involved in the care of patients with AMD. Credits: 1.0 ANCC Contact Hour.

CNE Accreditation Statement:

Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG‐sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

SriniVas Sadda, MD discloses the following financial interests or relationships:

  • Research Instruments: Carl Zeiss Meditec, Centervue, Heidelberg, Nidek, Optos, Topcon
  • Consultant: Genentech, MacuLogix, Regeneron, Notal Vision

CME Content Review

The content of this activity was independently peer-reviewed. The reviewer of this activity has nothing to disclose.

CNE Content Review

The content of this activity was peer-reviewed by a nurse reviewer.

Teresa L. Keating, MSN, RN, WHNP
Ultimate Medical Academy/CCM – Lead Nurse Planner

The reviewer of this activity has nothing to disclose

Staff Planners and Managers

The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

  • Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to d
  • Christina Gallo, SVP, Educational Development of Med Learning Group, has nothing to
  • Chris Drury, Director of Medical and Scientific Services of Med Learning Group, has nothing to disclose.
  • Teresa L. Keating, MSN, RN, WHNP, UMA/CMM – LNP, has nothing to disclose.
  • Ana Maria Albino, Senior Program Manager of Med Learning Group, has nothing to
  • Amanda Jenkins, Program Coordinator of Med Learning Group, has nothing to disclose.
  • Brianna Hanson, MPH, Outcomes and Accreditation Coordinator of Med Learning Group, has nothing to disclose.
  • Lauren Welch, MA, VP, Accreditation and Outcomes of Med Learning Group, has nothing to

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During the course of this lecture, the faculty may mention the use of medications for both FDA‐approved and non‐approved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this online activity. To receive CME/CNE credit participants must:

  1. Read the CME/CNE information and faculty disclosures;
  2. Participate in the online activity; and
  3. Complete pre-and-post surveys and evaluations.

You will receive your certificate as a downloadable file.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision‐making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at [email protected]

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]

RELEASE DATE: October 01, 2021

EXPIRATION DATE: October 01, 2022

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy‐policy/

Copyright © 2021 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form other than personal use without the express written permission of Med Learning Group is prohibited.

View Activity

Jul
23
Thu
Seeing Clearer: Optimizing the Use of Vascular Endothelial Growth Factor Inhibitors in Age Related Macular Degeneration – VA Grand Rounds Enduring Activity
Jul 23 2020 @ 7:55 am – Jul 23 2022 @ 8:55 am

Seeing Clearer: Optimizing the Use of VEGF Inhibitors in
Age-related Macular Degeneration (AMD)

View Activity

PROGRAM CHAIR

David Brown, MD

Director of Research, Retina Consultants of Texas

Clinical Professor of Ophthalmology, Baylor College of Medicine

Dallas, TX

 

PROGRAM OVERVIEW

This online activity targets healthcare gaps correlated with screening, multidisciplinary care and timely intervention in age-macular degeneration (AMD), which can impact vision-related quality of life.

  • By addressing these gaps, you can assess whether your approach to AMD management through screening, utilization of clinical trial data to guide appropriate treatment and multidisciplinary coordination for comprehensive AMD management – could be modified to help both strategize treatment design and close these gaps.
  • Expert discussion will guide you in identifying appropriate opportunities for early intervention, as well as assessing impact that AMD can have on vision-related quality of life.
  • You will also be immersed in dynamic whiteboard animations to memorably highlight key points related to how the inflammatory and vascular endothelial growth factor (VEGF) pathways lead to the development of AMD, as well as the fundoscopic retinal changes associated with each stage of AMD.

 

TARGET AUDIENCE

This online CME activity is designed to meet the educational needs of retina specialists, ophthalmologists, primary care providers, optometrists, managed care providers, pharmacists and other healthcare providers who manage patients with age-related macular degeneration.

 

LEARNING OBJECTIVES

  • Communicate the importance of proper eye care and early intervention in preventing progressive visual changes in patients with or at risk for AMD
  • Incorporate collaborative strategies into clinical practice that promote team-based communication, maintain continuity of care, and improve treatment adherence for patients with or who are at risk for AMD
  • Identify pathogenic changes in AMD that would be best managed with a multidisciplinary approach
  • Evaluate clinical trial data on the efficacy and safety of currently available treatment options for the management of AMD

 

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.

 

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this online activity for a maximum of 1.0 AMA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the online activity.

NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the care of patients with AMD.

CNE Credits: 1.0 ANCC Contact Hour.

CNE ACCREDITATION STATEMENT

Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission of Accreditation. Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturers of any commercial products and/or providers of commercial services that are discussed in an educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Faculty Member Disclosures
David Brown, MD Consulting work for Adverum, Alexion, Annexon Biosciences, Apellis, Boehringer Ingelheim, Celltrion, Clearside Biomedical, Dark Horse Consulting, Horizon Therapeutics, Genentech, Kodiak, Laboratories THEA, Lineage (BioTime), Novartis, Ocular Theapeutix, OPTOS, Regeneron, Retinal Medical, Senju Pharmaceutical and Verseon.

Grant funding from Adverum, Aldeyra, Apellis, Bayer, BIRC, Boehringer Ingelheim, Clearside Biomedical, Cleveland Clinic Foundation, F. Hoffmann-La Roche Limited, Gyroscope, Ionis, Iveric, Kodiak, Lowy Medical Research Institute, Lumithera, Nanoscope, NEI/NIH, NGM, Novartis, OIRRC, OPTOS, Oxurion, Regeneron, REGENXBIO, SamChunDang Pharma, Santen, Senju Pharmaceutical

 

CME Content Review

The content of this activity was independently peer reviewed.

The reviewer of this activity has nothing to disclose.

CNE Content Review

The content of this activity was peer reviewed by a nurse reviewer.

The reviewer of this activity has nothing to disclose.

Staff Planners and Managers

The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

  • Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
  • Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
  • Nicole Longo, DO, FACOI, Director of Medical and Scientific Services for Med Learning Group has nothing to disclose.
  • Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
  • Marissa Mays-Verman, Program Manager for Med Learning Group, has nothing to disclose.
  • Brianna Hanson, MPH, Accreditation and Outcomes Coordinator, has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this online activity. To receive CME/CNE credit participants must:

  1. Read the CME/CNE information and faculty disclosures.
  2. Participate in the online activity.
  3. Complete the online post-test and evaluation.

You will receive your certificate as a downloadable file.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are science based.

This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at [email protected]

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]

 

Copyright © 2021 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.

Jul
24
Fri
Seeing Clearer: Optimizing the Use of Vascular Endothelial Growth Factor Inhibitors in Age-related Macular Degeneration Immersive Simulation Experience
Jul 24 2020 @ 1:00 am – Jul 24 2022 @ 2:00 am

Seeing Clearer: Optimizing the Use of Vascular Endothelial Growth Factor Inhibitors in Age-related Macular Degeneration
Immersive Simulation Experience

View Activity

FACULTY


Allen C. Ho, MD, FACS
Attending Surgeon and Director of Retina Research, Wills Eye Hospital
Professor of Ophthalmology, Thomas Jefferson University
Mid Atlantic Retina
Philadelphia, PA

PROGRAM OVERVIEW

The Age-related Macular Degeneration (AMD) Immersive Simulation Experience allows learners to engage in clinical decision-making targeting diagnosis and therapeutic approaches in AMD management. By participating in this simulated 3D encounter, you will observe patient-provider interactions and use pertinent information from the patients’ electronic chart to decide the next best course of action at various key points in care. Highlighted areas for this activity include assessment of AMD classification, risk factor modification, interventions based on AMD classification, as well as the recognition and management of treatment-related adverse events.


TARGET AUDIENCE

This activity is designed to meet the educational needs of retina specialists, ophthalmologists, primary care providers, optometrists, and other healthcare providers who manage patients with age-related macular degeneration.


LEARNING OBJECTIVES

  • Communicate the importance of proper eye care and early intervention in preventing progressive visual changes in patients with or at risk for AMD
  • Incorporate collaborative strategies into clinical practice that promote team-based communication, maintain continuity of care, and improve treatment adherence for patients with or who are at risk for AMD
  • Identify pathogenic changes in AMD that would be best managed with a multidisciplinary approach
  • Evaluate clinical trial data on the efficacy and safety of currently available treatment options for the management of AMD

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.


CREDIT DESIGNATION STATEMENT

Med Learning Group designates this online activity for a maximum of 1.0 AMA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the online activity.


NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the care of patients with age-related macular degeneration.
CNE Credits: 1.0 ANCC Contact Hour.


CNE ACCREDITATION STATEMENT

Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.


DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturers of any commercial products and/or providers of commercial services that are discussed in an educational activity.


DISCLOSURE OF CONFLICTS OF INTEREST

Dr. Allen Ho discloses the following:

  • He is a consultant/advisor for Adverum Biotechnologies, Aerie Pharmaceuticals, Alcon Laboratories, Aldeyra Therapeutics, Allergan, Apellis Pharmaceuticals, Applied Genetic Technologies Corporation (AGTC), AsclepiX Therapeutics, Beaver-Visitec International, BioTime, Chengdu Kanghong Biotechnology, Genentech, Graybug Vision, Gyroscope Therapeutics, IRIDEX, Iveric/Ophthotech, Johnson & Johnson, Lineage Cell Therapeutics/ BioTime, Notal Vision, ONL Therapeutics, Optovue, PanOptica, Regeneron Pharmaceuticals, and REGENXBIO
  • He has received grants from Aerie, AGTC, Alcon Laboratories, Aldeyra, Allergan, Apellis, BioTime, Chengdu Kanghong Biotechnology, Genentech, Gemini Medical, Graybug Vision, Gyroscope, Iveric/Ophthotech, Johnson & Johnson, Lineage/BioTime, LumiThera, National Eye Institute, Novartis, Optovue, ProQR Therapeutics, Regeneron Pharmaceuticals, REGENXBIO, and Sanofi
  • He has ownership in Covalent Medical, ONL Therapeutics, and PanOptica

CME Content Review
The content of this activity was independently peer-reviewed.
The reviewer of this activity has nothing to disclose.

CNE Content Review
The content of this activity was peer-reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.

Staff, Planners, and Managers
The staff, planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Matthew Frese, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development of Med Learning Group, has nothing to disclose.
Ana Maria Albino, Senior Program Manager of Med Learning Group, has nothing to disclose.
Nicole Longo, DO, FACOI, Director of Medical and Scientific Services of Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP of Accreditation and Outcomes of Med Learning Group, has nothing to disclose.
Brianna Hanson, Accreditation and Outcomes Coordinator of Med Learning Group, has nothing to disclose.


DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During this lecture, faculty may mention the use of medications for both FDA-approved and non-approved indications.


METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this online activity. To receive CME/CNE credit participants must:

  1. Read the CME/CNE information and faculty disclosures;
  2. Participate in the online activity; and
  3. Complete pre-and-post surveys and evaluation.

You will receive your certificate as a downloadable file.


DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are science-based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at [email protected].

RELEASE DATE: April 2, 2021

EXPIRATION DATE: April 2, 2022

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected].

 

Copyright © 2021 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.

ONLINE ACTIVITIES

Jun
21
Sun
Seeing Past the Treatment Horizon: Anti-VEGF Therapies and Beyond in Retinal Disease Track: Age-related Macular Degeneration (Optometry)
Jun 21 2020 @ 9:00 am – Oct 1 2022 @ 10:00 am

Seeing Past the Treatment Horizon: Anti-VEGF Therapies and Beyond in Retinal Disease Track: Age-related Macular Degeneration (Optometry)

View Activity

FACULTY

Steven Ferrucci, OD, FAAO
Chief of Optometry, Sepulveda VA Medical Center
Los Angeles, CA
Professor, Southern California College of Optometry at Marshall B. Ketchum University
Fullerton, CA

PROGRAM OVERVIEW

This online activity targets healthcare gaps related to evidence-based recognition and prevention as well as timely treatment and management of age-related macular degeneration (AMD), impacting visual outcomes through guidelines and best practices, clinical trial data and strategies to facilitate earlier initiation of therapy.

  • By addressing these gaps, you can assess whether your approach to AMD management through utilization of current treatment guidelines, individualization of treatment approach and strategies for overcoming treatment barriers – could be modified to help close these gaps.
  • Expert discussion will guide you in analyzing and identifying appropriate candidates for anti-VEGF therapy, utilizing guidelines and clinical trial data on efficacy and safety to affect patient outcomes.
  • You will also be immersed in dynamic animations utilizing a virtual reality platform to memorably highlight key points related to anti-VEGF therapy in AMD and the recognition of retinal vasculitis.

TARGET AUDIENCE

This activity is designed to meet the educational needs of retina specialists, ophthalmologists, primary care providers, optometrists, and other healthcare providers who manage patients with age-related macular degeneration.

LEARNING OBJECTIVES

After completing the CME activity, learners should be better able to:

  • Incorporate consistent use of evidence-based screening and prevention strategies for patients at risk of AMD
  • Apply clinical trial data and guidelines to the selection of therapies for the treatment of patients with AMD
  • Identify barriers to early intervention and communicate to patients the importance for early initiation of therapy in AMD

ACCREDITATION STATEMENT: Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.

CREDIT DESIGNATION STATEMENT: Med Learning Group designates this online activity for a maximum of 1.25 AMA Category 1 creditTM. Physicians should claim only the credit commensurate with the extent of their participation in the live virtual activity.

NURSING CREDIT INFORMATION: Purpose: This program would be beneficial for nurses involved in the care of patients with AMD. Credits: 1.25 ANCC Contact Hour.

CNE Accreditation Statement:

Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 1.25 contact hour of continuing nursing education of RNs and APNs.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG‐sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Steven Ferrucc, OD, FAAO discloses the following financial interests or relationships:

  • Consultant: Centervue, Science Based Health, Visible Genomics
  • Speakers’ Bureau: Genentech, MacuLogix, Regeneron, Notal Vision

CME Content Review

The content of this activity was independently peer-reviewed. The reviewer of this activity has nothing to disclose.

CNE Content Review

The content of this activity was peer-reviewed by a nurse reviewer.

Teresa L. Keating, MSN, RN, WHNP
Ultimate Medical Academy/CCM – Lead Nurse Planner

The reviewer of this activity has nothing to disclose

Staff Planners and Managers

The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

  • Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to d
  • Christina Gallo, SVP, Educational Development of Med Learning Group, has nothing to
  • Chris Drury, Director of Medical and Scientific Services of Med Learning Group, has nothing to disclose.
  • Teresa L. Keating, MSN, RN, WHNP, UMA/CMM – LNP, has nothing to disclose.
  • Ana Maria Albino, Senior Program Manager of Med Learning Group, has nothing to
  • Amanda Jenkins, Program Coordinator of Med Learning Group, has nothing to disclose.
  • Brianna Hanson, MPH, Outcomes and Accreditation Coordinator of Med Learning Group, has nothing to disclose.
  • Lauren Welch, MA, VP, Accreditation and Outcomes of Med Learning Group, has nothing to

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During the course of this lecture, the faculty may mention the use of medications for both FDA‐approved and non‐approved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this online activity. To receive CME/CNE credit participants must:

  1. Read the CME/CNE information and faculty disclosures;
  2. Participate in the online activity; and
  3. Complete pre-and-post surveys and evaluations.

You will receive your certificate as a downloadable file.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision‐making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at [email protected]

RELEASE DATE: October 01, 2021

EXPIRATION DATE: October 01, 2022

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy‐policy/

Copyright © 2021 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form other than personal use without the express written permission of Med Learning Group is prohibited.

View Activity

Jun
22
Mon
Seeing Past the Treatment Horizon: Anti-VEGF Therapies and Beyond in Retinal Disease Track: Age-related Macular Degeneration (Retina/Ophthalmology)
Jun 22 2020 @ 9:00 am – Oct 1 2022 @ 10:00 am

Seeing Past the Treatment Horizon: Anti-VEGF Therapies and Beyond in Retinal Disease Track: Age-related Macular Degeneration (Retina/Ophthalmology)

View Activity

FACULTY

SriniVas Sadda, MD
Professor of Ophthalmology
Doheny Eye Institute
David Geffen School of Medicine
University of California – Los Angeles

PROGRAM OVERVIEW

This online activity targets healthcare gaps related to evidence-based recognition and prevention as well as timely treatment and management of age-related macular degeneration (AMD), impacting visual outcomes through guidelines and best practices, clinical trial data and strategies to facilitate earlier initiation of therapy.

  • By addressing these gaps, you can assess whether your approach to AMD management through utilization of current treatment guidelines, individualization of treatment approach and strategies for overcoming treatment barriers – could be modified to help close these gaps.
  • Expert discussion will guide you in analyzing and identifying appropriate candidates for anti-VEGF therapy, utilizing guidelines and clinical trial data on efficacy and safety to affect patient outcomes.
  • You will also be immersed in dynamic animations utilizing a virtual reality platform to memorably highlight key points related to anti-VEGF therapy in AMD and the recognition of retinal vasculitis.

TARGET AUDIENCE

This activity is designed to meet the educational needs of retina specialists, ophthalmologists, primary care providers, optometrists, and other healthcare providers who manage patients with age-related macular degeneration.

LEARNING OBJECTIVES

After completing the CME activity, learners should be better able to:

  • Incorporate consistent use of evidence-based screening and prevention strategies for patients at risk of AMD
  • Apply clinical trial data and guidelines to the selection of therapies for the treatment of patients with AMD
  • Identify barriers to early intervention and communicate to patients the importance for early initiation of therapy in AMD

ACCREDITATION STATEMENT: Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.

CREDIT DESIGNATION STATEMENT: Med Learning Group designates this online activity for a maximum of 1.0 AMA Category 1 creditTM. Physicians should claim only the credit commensurate with the extent of their participation in the live virtual activity.

NURSING CREDIT INFORMATION: Purpose: This program would be beneficial for nurses involved in the care of patients with AMD. Credits: 1.0 ANCC Contact Hour.

CNE Accreditation Statement:

Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG‐sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

SriniVas Sadda, MD discloses the following financial interests or relationships:

  • Research Instruments: Carl Zeiss Meditec, Centervue, Heidelberg, Nidek, Optos, Topcon
  • Consultant: Genentech, MacuLogix, Regeneron, Notal Vision

CME Content Review

The content of this activity was independently peer-reviewed. The reviewer of this activity has nothing to disclose.

CNE Content Review

The content of this activity was peer-reviewed by a nurse reviewer.

Teresa L. Keating, MSN, RN, WHNP
Ultimate Medical Academy/CCM – Lead Nurse Planner

The reviewer of this activity has nothing to disclose

Staff Planners and Managers

The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

  • Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to d
  • Christina Gallo, SVP, Educational Development of Med Learning Group, has nothing to
  • Chris Drury, Director of Medical and Scientific Services of Med Learning Group, has nothing to disclose.
  • Teresa L. Keating, MSN, RN, WHNP, UMA/CMM – LNP, has nothing to disclose.
  • Ana Maria Albino, Senior Program Manager of Med Learning Group, has nothing to
  • Amanda Jenkins, Program Coordinator of Med Learning Group, has nothing to disclose.
  • Brianna Hanson, MPH, Outcomes and Accreditation Coordinator of Med Learning Group, has nothing to disclose.
  • Lauren Welch, MA, VP, Accreditation and Outcomes of Med Learning Group, has nothing to

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During the course of this lecture, the faculty may mention the use of medications for both FDA‐approved and non‐approved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this online activity. To receive CME/CNE credit participants must:

  1. Read the CME/CNE information and faculty disclosures;
  2. Participate in the online activity; and
  3. Complete pre-and-post surveys and evaluations.

You will receive your certificate as a downloadable file.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision‐making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at [email protected]

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]

RELEASE DATE: October 01, 2021

EXPIRATION DATE: October 01, 2022

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy‐policy/

Copyright © 2021 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form other than personal use without the express written permission of Med Learning Group is prohibited.

View Activity

Jul
23
Thu
Seeing Clearer: Optimizing the Use of Vascular Endothelial Growth Factor Inhibitors in Age Related Macular Degeneration – VA Grand Rounds Enduring Activity
Jul 23 2020 @ 7:55 am – Jul 23 2022 @ 8:55 am

Seeing Clearer: Optimizing the Use of VEGF Inhibitors in
Age-related Macular Degeneration (AMD)

View Activity

PROGRAM CHAIR

David Brown, MD

Director of Research, Retina Consultants of Texas

Clinical Professor of Ophthalmology, Baylor College of Medicine

Dallas, TX

 

PROGRAM OVERVIEW

This online activity targets healthcare gaps correlated with screening, multidisciplinary care and timely intervention in age-macular degeneration (AMD), which can impact vision-related quality of life.

  • By addressing these gaps, you can assess whether your approach to AMD management through screening, utilization of clinical trial data to guide appropriate treatment and multidisciplinary coordination for comprehensive AMD management – could be modified to help both strategize treatment design and close these gaps.
  • Expert discussion will guide you in identifying appropriate opportunities for early intervention, as well as assessing impact that AMD can have on vision-related quality of life.
  • You will also be immersed in dynamic whiteboard animations to memorably highlight key points related to how the inflammatory and vascular endothelial growth factor (VEGF) pathways lead to the development of AMD, as well as the fundoscopic retinal changes associated with each stage of AMD.

 

TARGET AUDIENCE

This online CME activity is designed to meet the educational needs of retina specialists, ophthalmologists, primary care providers, optometrists, managed care providers, pharmacists and other healthcare providers who manage patients with age-related macular degeneration.

 

LEARNING OBJECTIVES

  • Communicate the importance of proper eye care and early intervention in preventing progressive visual changes in patients with or at risk for AMD
  • Incorporate collaborative strategies into clinical practice that promote team-based communication, maintain continuity of care, and improve treatment adherence for patients with or who are at risk for AMD
  • Identify pathogenic changes in AMD that would be best managed with a multidisciplinary approach
  • Evaluate clinical trial data on the efficacy and safety of currently available treatment options for the management of AMD

 

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.

 

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this online activity for a maximum of 1.0 AMA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the online activity.

NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the care of patients with AMD.

CNE Credits: 1.0 ANCC Contact Hour.

CNE ACCREDITATION STATEMENT

Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission of Accreditation. Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturers of any commercial products and/or providers of commercial services that are discussed in an educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Faculty Member Disclosures
David Brown, MD Consulting work for Adverum, Alexion, Annexon Biosciences, Apellis, Boehringer Ingelheim, Celltrion, Clearside Biomedical, Dark Horse Consulting, Horizon Therapeutics, Genentech, Kodiak, Laboratories THEA, Lineage (BioTime), Novartis, Ocular Theapeutix, OPTOS, Regeneron, Retinal Medical, Senju Pharmaceutical and Verseon.

Grant funding from Adverum, Aldeyra, Apellis, Bayer, BIRC, Boehringer Ingelheim, Clearside Biomedical, Cleveland Clinic Foundation, F. Hoffmann-La Roche Limited, Gyroscope, Ionis, Iveric, Kodiak, Lowy Medical Research Institute, Lumithera, Nanoscope, NEI/NIH, NGM, Novartis, OIRRC, OPTOS, Oxurion, Regeneron, REGENXBIO, SamChunDang Pharma, Santen, Senju Pharmaceutical

 

CME Content Review

The content of this activity was independently peer reviewed.

The reviewer of this activity has nothing to disclose.

CNE Content Review

The content of this activity was peer reviewed by a nurse reviewer.

The reviewer of this activity has nothing to disclose.

Staff Planners and Managers

The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

  • Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
  • Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
  • Nicole Longo, DO, FACOI, Director of Medical and Scientific Services for Med Learning Group has nothing to disclose.
  • Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
  • Marissa Mays-Verman, Program Manager for Med Learning Group, has nothing to disclose.
  • Brianna Hanson, MPH, Accreditation and Outcomes Coordinator, has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this online activity. To receive CME/CNE credit participants must:

  1. Read the CME/CNE information and faculty disclosures.
  2. Participate in the online activity.
  3. Complete the online post-test and evaluation.

You will receive your certificate as a downloadable file.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are science based.

This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at [email protected]

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]

 

Copyright © 2021 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.

Jul
24
Fri
Seeing Clearer: Optimizing the Use of Vascular Endothelial Growth Factor Inhibitors in Age-related Macular Degeneration Immersive Simulation Experience
Jul 24 2020 @ 1:00 am – Jul 24 2022 @ 2:00 am

Seeing Clearer: Optimizing the Use of Vascular Endothelial Growth Factor Inhibitors in Age-related Macular Degeneration
Immersive Simulation Experience

View Activity

FACULTY


Allen C. Ho, MD, FACS
Attending Surgeon and Director of Retina Research, Wills Eye Hospital
Professor of Ophthalmology, Thomas Jefferson University
Mid Atlantic Retina
Philadelphia, PA

PROGRAM OVERVIEW

The Age-related Macular Degeneration (AMD) Immersive Simulation Experience allows learners to engage in clinical decision-making targeting diagnosis and therapeutic approaches in AMD management. By participating in this simulated 3D encounter, you will observe patient-provider interactions and use pertinent information from the patients’ electronic chart to decide the next best course of action at various key points in care. Highlighted areas for this activity include assessment of AMD classification, risk factor modification, interventions based on AMD classification, as well as the recognition and management of treatment-related adverse events.


TARGET AUDIENCE

This activity is designed to meet the educational needs of retina specialists, ophthalmologists, primary care providers, optometrists, and other healthcare providers who manage patients with age-related macular degeneration.


LEARNING OBJECTIVES

  • Communicate the importance of proper eye care and early intervention in preventing progressive visual changes in patients with or at risk for AMD
  • Incorporate collaborative strategies into clinical practice that promote team-based communication, maintain continuity of care, and improve treatment adherence for patients with or who are at risk for AMD
  • Identify pathogenic changes in AMD that would be best managed with a multidisciplinary approach
  • Evaluate clinical trial data on the efficacy and safety of currently available treatment options for the management of AMD

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.


CREDIT DESIGNATION STATEMENT

Med Learning Group designates this online activity for a maximum of 1.0 AMA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the online activity.


NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the care of patients with age-related macular degeneration.
CNE Credits: 1.0 ANCC Contact Hour.


CNE ACCREDITATION STATEMENT

Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.


DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturers of any commercial products and/or providers of commercial services that are discussed in an educational activity.


DISCLOSURE OF CONFLICTS OF INTEREST

Dr. Allen Ho discloses the following:

  • He is a consultant/advisor for Adverum Biotechnologies, Aerie Pharmaceuticals, Alcon Laboratories, Aldeyra Therapeutics, Allergan, Apellis Pharmaceuticals, Applied Genetic Technologies Corporation (AGTC), AsclepiX Therapeutics, Beaver-Visitec International, BioTime, Chengdu Kanghong Biotechnology, Genentech, Graybug Vision, Gyroscope Therapeutics, IRIDEX, Iveric/Ophthotech, Johnson & Johnson, Lineage Cell Therapeutics/ BioTime, Notal Vision, ONL Therapeutics, Optovue, PanOptica, Regeneron Pharmaceuticals, and REGENXBIO
  • He has received grants from Aerie, AGTC, Alcon Laboratories, Aldeyra, Allergan, Apellis, BioTime, Chengdu Kanghong Biotechnology, Genentech, Gemini Medical, Graybug Vision, Gyroscope, Iveric/Ophthotech, Johnson & Johnson, Lineage/BioTime, LumiThera, National Eye Institute, Novartis, Optovue, ProQR Therapeutics, Regeneron Pharmaceuticals, REGENXBIO, and Sanofi
  • He has ownership in Covalent Medical, ONL Therapeutics, and PanOptica

CME Content Review
The content of this activity was independently peer-reviewed.
The reviewer of this activity has nothing to disclose.

CNE Content Review
The content of this activity was peer-reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.

Staff, Planners, and Managers
The staff, planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Matthew Frese, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development of Med Learning Group, has nothing to disclose.
Ana Maria Albino, Senior Program Manager of Med Learning Group, has nothing to disclose.
Nicole Longo, DO, FACOI, Director of Medical and Scientific Services of Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP of Accreditation and Outcomes of Med Learning Group, has nothing to disclose.
Brianna Hanson, Accreditation and Outcomes Coordinator of Med Learning Group, has nothing to disclose.


DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During this lecture, faculty may mention the use of medications for both FDA-approved and non-approved indications.


METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this online activity. To receive CME/CNE credit participants must:

  1. Read the CME/CNE information and faculty disclosures;
  2. Participate in the online activity; and
  3. Complete pre-and-post surveys and evaluation.

You will receive your certificate as a downloadable file.


DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are science-based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at [email protected].

RELEASE DATE: April 2, 2021

EXPIRATION DATE: April 2, 2022

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected].

 

Copyright © 2021 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.

Jun
21
Sun
Seeing Past the Treatment Horizon: Anti-VEGF Therapies and Beyond in Retinal Disease Track: Age-related Macular Degeneration (Optometry)
Jun 21 2020 @ 9:00 am – Oct 1 2022 @ 10:00 am

Seeing Past the Treatment Horizon: Anti-VEGF Therapies and Beyond in Retinal Disease Track: Age-related Macular Degeneration (Optometry)

View Activity

FACULTY

Steven Ferrucci, OD, FAAO
Chief of Optometry, Sepulveda VA Medical Center
Los Angeles, CA
Professor, Southern California College of Optometry at Marshall B. Ketchum University
Fullerton, CA

PROGRAM OVERVIEW

This online activity targets healthcare gaps related to evidence-based recognition and prevention as well as timely treatment and management of age-related macular degeneration (AMD), impacting visual outcomes through guidelines and best practices, clinical trial data and strategies to facilitate earlier initiation of therapy.

  • By addressing these gaps, you can assess whether your approach to AMD management through utilization of current treatment guidelines, individualization of treatment approach and strategies for overcoming treatment barriers – could be modified to help close these gaps.
  • Expert discussion will guide you in analyzing and identifying appropriate candidates for anti-VEGF therapy, utilizing guidelines and clinical trial data on efficacy and safety to affect patient outcomes.
  • You will also be immersed in dynamic animations utilizing a virtual reality platform to memorably highlight key points related to anti-VEGF therapy in AMD and the recognition of retinal vasculitis.

TARGET AUDIENCE

This activity is designed to meet the educational needs of retina specialists, ophthalmologists, primary care providers, optometrists, and other healthcare providers who manage patients with age-related macular degeneration.

LEARNING OBJECTIVES

After completing the CME activity, learners should be better able to:

  • Incorporate consistent use of evidence-based screening and prevention strategies for patients at risk of AMD
  • Apply clinical trial data and guidelines to the selection of therapies for the treatment of patients with AMD
  • Identify barriers to early intervention and communicate to patients the importance for early initiation of therapy in AMD

ACCREDITATION STATEMENT: Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.

CREDIT DESIGNATION STATEMENT: Med Learning Group designates this online activity for a maximum of 1.25 AMA Category 1 creditTM. Physicians should claim only the credit commensurate with the extent of their participation in the live virtual activity.

NURSING CREDIT INFORMATION: Purpose: This program would be beneficial for nurses involved in the care of patients with AMD. Credits: 1.25 ANCC Contact Hour.

CNE Accreditation Statement:

Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 1.25 contact hour of continuing nursing education of RNs and APNs.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG‐sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Steven Ferrucc, OD, FAAO discloses the following financial interests or relationships:

  • Consultant: Centervue, Science Based Health, Visible Genomics
  • Speakers’ Bureau: Genentech, MacuLogix, Regeneron, Notal Vision

CME Content Review

The content of this activity was independently peer-reviewed. The reviewer of this activity has nothing to disclose.

CNE Content Review

The content of this activity was peer-reviewed by a nurse reviewer.

Teresa L. Keating, MSN, RN, WHNP
Ultimate Medical Academy/CCM – Lead Nurse Planner

The reviewer of this activity has nothing to disclose

Staff Planners and Managers

The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

  • Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to d
  • Christina Gallo, SVP, Educational Development of Med Learning Group, has nothing to
  • Chris Drury, Director of Medical and Scientific Services of Med Learning Group, has nothing to disclose.
  • Teresa L. Keating, MSN, RN, WHNP, UMA/CMM – LNP, has nothing to disclose.
  • Ana Maria Albino, Senior Program Manager of Med Learning Group, has nothing to
  • Amanda Jenkins, Program Coordinator of Med Learning Group, has nothing to disclose.
  • Brianna Hanson, MPH, Outcomes and Accreditation Coordinator of Med Learning Group, has nothing to disclose.
  • Lauren Welch, MA, VP, Accreditation and Outcomes of Med Learning Group, has nothing to

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During the course of this lecture, the faculty may mention the use of medications for both FDA‐approved and non‐approved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this online activity. To receive CME/CNE credit participants must:

  1. Read the CME/CNE information and faculty disclosures;
  2. Participate in the online activity; and
  3. Complete pre-and-post surveys and evaluations.

You will receive your certificate as a downloadable file.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision‐making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at [email protected]

RELEASE DATE: October 01, 2021

EXPIRATION DATE: October 01, 2022

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy‐policy/

Copyright © 2021 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form other than personal use without the express written permission of Med Learning Group is prohibited.

View Activity

Jun
22
Mon
Seeing Past the Treatment Horizon: Anti-VEGF Therapies and Beyond in Retinal Disease Track: Age-related Macular Degeneration (Retina/Ophthalmology)
Jun 22 2020 @ 9:00 am – Oct 1 2022 @ 10:00 am

Seeing Past the Treatment Horizon: Anti-VEGF Therapies and Beyond in Retinal Disease Track: Age-related Macular Degeneration (Retina/Ophthalmology)

View Activity

FACULTY

SriniVas Sadda, MD
Professor of Ophthalmology
Doheny Eye Institute
David Geffen School of Medicine
University of California – Los Angeles

PROGRAM OVERVIEW

This online activity targets healthcare gaps related to evidence-based recognition and prevention as well as timely treatment and management of age-related macular degeneration (AMD), impacting visual outcomes through guidelines and best practices, clinical trial data and strategies to facilitate earlier initiation of therapy.

  • By addressing these gaps, you can assess whether your approach to AMD management through utilization of current treatment guidelines, individualization of treatment approach and strategies for overcoming treatment barriers – could be modified to help close these gaps.
  • Expert discussion will guide you in analyzing and identifying appropriate candidates for anti-VEGF therapy, utilizing guidelines and clinical trial data on efficacy and safety to affect patient outcomes.
  • You will also be immersed in dynamic animations utilizing a virtual reality platform to memorably highlight key points related to anti-VEGF therapy in AMD and the recognition of retinal vasculitis.

TARGET AUDIENCE

This activity is designed to meet the educational needs of retina specialists, ophthalmologists, primary care providers, optometrists, and other healthcare providers who manage patients with age-related macular degeneration.

LEARNING OBJECTIVES

After completing the CME activity, learners should be better able to:

  • Incorporate consistent use of evidence-based screening and prevention strategies for patients at risk of AMD
  • Apply clinical trial data and guidelines to the selection of therapies for the treatment of patients with AMD
  • Identify barriers to early intervention and communicate to patients the importance for early initiation of therapy in AMD

ACCREDITATION STATEMENT: Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.

CREDIT DESIGNATION STATEMENT: Med Learning Group designates this online activity for a maximum of 1.0 AMA Category 1 creditTM. Physicians should claim only the credit commensurate with the extent of their participation in the live virtual activity.

NURSING CREDIT INFORMATION: Purpose: This program would be beneficial for nurses involved in the care of patients with AMD. Credits: 1.0 ANCC Contact Hour.

CNE Accreditation Statement:

Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG‐sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

SriniVas Sadda, MD discloses the following financial interests or relationships:

  • Research Instruments: Carl Zeiss Meditec, Centervue, Heidelberg, Nidek, Optos, Topcon
  • Consultant: Genentech, MacuLogix, Regeneron, Notal Vision

CME Content Review

The content of this activity was independently peer-reviewed. The reviewer of this activity has nothing to disclose.

CNE Content Review

The content of this activity was peer-reviewed by a nurse reviewer.

Teresa L. Keating, MSN, RN, WHNP
Ultimate Medical Academy/CCM – Lead Nurse Planner

The reviewer of this activity has nothing to disclose

Staff Planners and Managers

The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

  • Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to d
  • Christina Gallo, SVP, Educational Development of Med Learning Group, has nothing to
  • Chris Drury, Director of Medical and Scientific Services of Med Learning Group, has nothing to disclose.
  • Teresa L. Keating, MSN, RN, WHNP, UMA/CMM – LNP, has nothing to disclose.
  • Ana Maria Albino, Senior Program Manager of Med Learning Group, has nothing to
  • Amanda Jenkins, Program Coordinator of Med Learning Group, has nothing to disclose.
  • Brianna Hanson, MPH, Outcomes and Accreditation Coordinator of Med Learning Group, has nothing to disclose.
  • Lauren Welch, MA, VP, Accreditation and Outcomes of Med Learning Group, has nothing to

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During the course of this lecture, the faculty may mention the use of medications for both FDA‐approved and non‐approved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this online activity. To receive CME/CNE credit participants must:

  1. Read the CME/CNE information and faculty disclosures;
  2. Participate in the online activity; and
  3. Complete pre-and-post surveys and evaluations.

You will receive your certificate as a downloadable file.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision‐making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at [email protected]

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]

RELEASE DATE: October 01, 2021

EXPIRATION DATE: October 01, 2022

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy‐policy/

Copyright © 2021 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form other than personal use without the express written permission of Med Learning Group is prohibited.

View Activity

Jul
23
Thu
Seeing Clearer: Optimizing the Use of Vascular Endothelial Growth Factor Inhibitors in Age Related Macular Degeneration – VA Grand Rounds Enduring Activity
Jul 23 2020 @ 7:55 am – Jul 23 2022 @ 8:55 am

Seeing Clearer: Optimizing the Use of VEGF Inhibitors in
Age-related Macular Degeneration (AMD)

View Activity

PROGRAM CHAIR

David Brown, MD

Director of Research, Retina Consultants of Texas

Clinical Professor of Ophthalmology, Baylor College of Medicine

Dallas, TX

 

PROGRAM OVERVIEW

This online activity targets healthcare gaps correlated with screening, multidisciplinary care and timely intervention in age-macular degeneration (AMD), which can impact vision-related quality of life.

  • By addressing these gaps, you can assess whether your approach to AMD management through screening, utilization of clinical trial data to guide appropriate treatment and multidisciplinary coordination for comprehensive AMD management – could be modified to help both strategize treatment design and close these gaps.
  • Expert discussion will guide you in identifying appropriate opportunities for early intervention, as well as assessing impact that AMD can have on vision-related quality of life.
  • You will also be immersed in dynamic whiteboard animations to memorably highlight key points related to how the inflammatory and vascular endothelial growth factor (VEGF) pathways lead to the development of AMD, as well as the fundoscopic retinal changes associated with each stage of AMD.

 

TARGET AUDIENCE

This online CME activity is designed to meet the educational needs of retina specialists, ophthalmologists, primary care providers, optometrists, managed care providers, pharmacists and other healthcare providers who manage patients with age-related macular degeneration.

 

LEARNING OBJECTIVES

  • Communicate the importance of proper eye care and early intervention in preventing progressive visual changes in patients with or at risk for AMD
  • Incorporate collaborative strategies into clinical practice that promote team-based communication, maintain continuity of care, and improve treatment adherence for patients with or who are at risk for AMD
  • Identify pathogenic changes in AMD that would be best managed with a multidisciplinary approach
  • Evaluate clinical trial data on the efficacy and safety of currently available treatment options for the management of AMD

 

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.

 

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this online activity for a maximum of 1.0 AMA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the online activity.

NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the care of patients with AMD.

CNE Credits: 1.0 ANCC Contact Hour.

CNE ACCREDITATION STATEMENT

Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission of Accreditation. Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturers of any commercial products and/or providers of commercial services that are discussed in an educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Faculty Member Disclosures
David Brown, MD Consulting work for Adverum, Alexion, Annexon Biosciences, Apellis, Boehringer Ingelheim, Celltrion, Clearside Biomedical, Dark Horse Consulting, Horizon Therapeutics, Genentech, Kodiak, Laboratories THEA, Lineage (BioTime), Novartis, Ocular Theapeutix, OPTOS, Regeneron, Retinal Medical, Senju Pharmaceutical and Verseon.

Grant funding from Adverum, Aldeyra, Apellis, Bayer, BIRC, Boehringer Ingelheim, Clearside Biomedical, Cleveland Clinic Foundation, F. Hoffmann-La Roche Limited, Gyroscope, Ionis, Iveric, Kodiak, Lowy Medical Research Institute, Lumithera, Nanoscope, NEI/NIH, NGM, Novartis, OIRRC, OPTOS, Oxurion, Regeneron, REGENXBIO, SamChunDang Pharma, Santen, Senju Pharmaceutical

 

CME Content Review

The content of this activity was independently peer reviewed.

The reviewer of this activity has nothing to disclose.

CNE Content Review

The content of this activity was peer reviewed by a nurse reviewer.

The reviewer of this activity has nothing to disclose.

Staff Planners and Managers

The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

  • Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
  • Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
  • Nicole Longo, DO, FACOI, Director of Medical and Scientific Services for Med Learning Group has nothing to disclose.
  • Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
  • Marissa Mays-Verman, Program Manager for Med Learning Group, has nothing to disclose.
  • Brianna Hanson, MPH, Accreditation and Outcomes Coordinator, has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this online activity. To receive CME/CNE credit participants must:

  1. Read the CME/CNE information and faculty disclosures.
  2. Participate in the online activity.
  3. Complete the online post-test and evaluation.

You will receive your certificate as a downloadable file.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are science based.

This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at [email protected]

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]

 

Copyright © 2021 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.

Jul
24
Fri
Seeing Clearer: Optimizing the Use of Vascular Endothelial Growth Factor Inhibitors in Age-related Macular Degeneration Immersive Simulation Experience
Jul 24 2020 @ 1:00 am – Jul 24 2022 @ 2:00 am

Seeing Clearer: Optimizing the Use of Vascular Endothelial Growth Factor Inhibitors in Age-related Macular Degeneration
Immersive Simulation Experience

View Activity

FACULTY


Allen C. Ho, MD, FACS
Attending Surgeon and Director of Retina Research, Wills Eye Hospital
Professor of Ophthalmology, Thomas Jefferson University
Mid Atlantic Retina
Philadelphia, PA

PROGRAM OVERVIEW

The Age-related Macular Degeneration (AMD) Immersive Simulation Experience allows learners to engage in clinical decision-making targeting diagnosis and therapeutic approaches in AMD management. By participating in this simulated 3D encounter, you will observe patient-provider interactions and use pertinent information from the patients’ electronic chart to decide the next best course of action at various key points in care. Highlighted areas for this activity include assessment of AMD classification, risk factor modification, interventions based on AMD classification, as well as the recognition and management of treatment-related adverse events.


TARGET AUDIENCE

This activity is designed to meet the educational needs of retina specialists, ophthalmologists, primary care providers, optometrists, and other healthcare providers who manage patients with age-related macular degeneration.


LEARNING OBJECTIVES

  • Communicate the importance of proper eye care and early intervention in preventing progressive visual changes in patients with or at risk for AMD
  • Incorporate collaborative strategies into clinical practice that promote team-based communication, maintain continuity of care, and improve treatment adherence for patients with or who are at risk for AMD
  • Identify pathogenic changes in AMD that would be best managed with a multidisciplinary approach
  • Evaluate clinical trial data on the efficacy and safety of currently available treatment options for the management of AMD

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.


CREDIT DESIGNATION STATEMENT

Med Learning Group designates this online activity for a maximum of 1.0 AMA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the online activity.


NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the care of patients with age-related macular degeneration.
CNE Credits: 1.0 ANCC Contact Hour.


CNE ACCREDITATION STATEMENT

Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.


DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturers of any commercial products and/or providers of commercial services that are discussed in an educational activity.


DISCLOSURE OF CONFLICTS OF INTEREST

Dr. Allen Ho discloses the following:

  • He is a consultant/advisor for Adverum Biotechnologies, Aerie Pharmaceuticals, Alcon Laboratories, Aldeyra Therapeutics, Allergan, Apellis Pharmaceuticals, Applied Genetic Technologies Corporation (AGTC), AsclepiX Therapeutics, Beaver-Visitec International, BioTime, Chengdu Kanghong Biotechnology, Genentech, Graybug Vision, Gyroscope Therapeutics, IRIDEX, Iveric/Ophthotech, Johnson & Johnson, Lineage Cell Therapeutics/ BioTime, Notal Vision, ONL Therapeutics, Optovue, PanOptica, Regeneron Pharmaceuticals, and REGENXBIO
  • He has received grants from Aerie, AGTC, Alcon Laboratories, Aldeyra, Allergan, Apellis, BioTime, Chengdu Kanghong Biotechnology, Genentech, Gemini Medical, Graybug Vision, Gyroscope, Iveric/Ophthotech, Johnson & Johnson, Lineage/BioTime, LumiThera, National Eye Institute, Novartis, Optovue, ProQR Therapeutics, Regeneron Pharmaceuticals, REGENXBIO, and Sanofi
  • He has ownership in Covalent Medical, ONL Therapeutics, and PanOptica

CME Content Review
The content of this activity was independently peer-reviewed.
The reviewer of this activity has nothing to disclose.

CNE Content Review
The content of this activity was peer-reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.

Staff, Planners, and Managers
The staff, planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Matthew Frese, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development of Med Learning Group, has nothing to disclose.
Ana Maria Albino, Senior Program Manager of Med Learning Group, has nothing to disclose.
Nicole Longo, DO, FACOI, Director of Medical and Scientific Services of Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP of Accreditation and Outcomes of Med Learning Group, has nothing to disclose.
Brianna Hanson, Accreditation and Outcomes Coordinator of Med Learning Group, has nothing to disclose.


DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During this lecture, faculty may mention the use of medications for both FDA-approved and non-approved indications.


METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this online activity. To receive CME/CNE credit participants must:

  1. Read the CME/CNE information and faculty disclosures;
  2. Participate in the online activity; and
  3. Complete pre-and-post surveys and evaluation.

You will receive your certificate as a downloadable file.


DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are science-based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at [email protected].

RELEASE DATE: April 2, 2021

EXPIRATION DATE: April 2, 2022

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected].

 

Copyright © 2021 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.

A Virtual Reality Learning Experience: Integrating GLP-1 Receptor Agonists into T2DM Practice—Why, When, and How

Jun
21
Sun
Seeing Past the Treatment Horizon: Anti-VEGF Therapies and Beyond in Retinal Disease Track: Age-related Macular Degeneration (Optometry)
Jun 21 2020 @ 9:00 am – Oct 1 2022 @ 10:00 am

Seeing Past the Treatment Horizon: Anti-VEGF Therapies and Beyond in Retinal Disease Track: Age-related Macular Degeneration (Optometry)

View Activity

FACULTY

Steven Ferrucci, OD, FAAO
Chief of Optometry, Sepulveda VA Medical Center
Los Angeles, CA
Professor, Southern California College of Optometry at Marshall B. Ketchum University
Fullerton, CA

PROGRAM OVERVIEW

This online activity targets healthcare gaps related to evidence-based recognition and prevention as well as timely treatment and management of age-related macular degeneration (AMD), impacting visual outcomes through guidelines and best practices, clinical trial data and strategies to facilitate earlier initiation of therapy.

  • By addressing these gaps, you can assess whether your approach to AMD management through utilization of current treatment guidelines, individualization of treatment approach and strategies for overcoming treatment barriers – could be modified to help close these gaps.
  • Expert discussion will guide you in analyzing and identifying appropriate candidates for anti-VEGF therapy, utilizing guidelines and clinical trial data on efficacy and safety to affect patient outcomes.
  • You will also be immersed in dynamic animations utilizing a virtual reality platform to memorably highlight key points related to anti-VEGF therapy in AMD and the recognition of retinal vasculitis.

TARGET AUDIENCE

This activity is designed to meet the educational needs of retina specialists, ophthalmologists, primary care providers, optometrists, and other healthcare providers who manage patients with age-related macular degeneration.

LEARNING OBJECTIVES

After completing the CME activity, learners should be better able to:

  • Incorporate consistent use of evidence-based screening and prevention strategies for patients at risk of AMD
  • Apply clinical trial data and guidelines to the selection of therapies for the treatment of patients with AMD
  • Identify barriers to early intervention and communicate to patients the importance for early initiation of therapy in AMD

ACCREDITATION STATEMENT: Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.

CREDIT DESIGNATION STATEMENT: Med Learning Group designates this online activity for a maximum of 1.25 AMA Category 1 creditTM. Physicians should claim only the credit commensurate with the extent of their participation in the live virtual activity.

NURSING CREDIT INFORMATION: Purpose: This program would be beneficial for nurses involved in the care of patients with AMD. Credits: 1.25 ANCC Contact Hour.

CNE Accreditation Statement:

Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 1.25 contact hour of continuing nursing education of RNs and APNs.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG‐sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Steven Ferrucc, OD, FAAO discloses the following financial interests or relationships:

  • Consultant: Centervue, Science Based Health, Visible Genomics
  • Speakers’ Bureau: Genentech, MacuLogix, Regeneron, Notal Vision

CME Content Review

The content of this activity was independently peer-reviewed. The reviewer of this activity has nothing to disclose.

CNE Content Review

The content of this activity was peer-reviewed by a nurse reviewer.

Teresa L. Keating, MSN, RN, WHNP
Ultimate Medical Academy/CCM – Lead Nurse Planner

The reviewer of this activity has nothing to disclose

Staff Planners and Managers

The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

  • Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to d
  • Christina Gallo, SVP, Educational Development of Med Learning Group, has nothing to
  • Chris Drury, Director of Medical and Scientific Services of Med Learning Group, has nothing to disclose.
  • Teresa L. Keating, MSN, RN, WHNP, UMA/CMM – LNP, has nothing to disclose.
  • Ana Maria Albino, Senior Program Manager of Med Learning Group, has nothing to
  • Amanda Jenkins, Program Coordinator of Med Learning Group, has nothing to disclose.
  • Brianna Hanson, MPH, Outcomes and Accreditation Coordinator of Med Learning Group, has nothing to disclose.
  • Lauren Welch, MA, VP, Accreditation and Outcomes of Med Learning Group, has nothing to

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During the course of this lecture, the faculty may mention the use of medications for both FDA‐approved and non‐approved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this online activity. To receive CME/CNE credit participants must:

  1. Read the CME/CNE information and faculty disclosures;
  2. Participate in the online activity; and
  3. Complete pre-and-post surveys and evaluations.

You will receive your certificate as a downloadable file.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision‐making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at [email protected]

RELEASE DATE: October 01, 2021

EXPIRATION DATE: October 01, 2022

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy‐policy/

Copyright © 2021 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form other than personal use without the express written permission of Med Learning Group is prohibited.

View Activity

Jun
22
Mon
Seeing Past the Treatment Horizon: Anti-VEGF Therapies and Beyond in Retinal Disease Track: Age-related Macular Degeneration (Retina/Ophthalmology)
Jun 22 2020 @ 9:00 am – Oct 1 2022 @ 10:00 am

Seeing Past the Treatment Horizon: Anti-VEGF Therapies and Beyond in Retinal Disease Track: Age-related Macular Degeneration (Retina/Ophthalmology)

View Activity

FACULTY

SriniVas Sadda, MD
Professor of Ophthalmology
Doheny Eye Institute
David Geffen School of Medicine
University of California – Los Angeles

PROGRAM OVERVIEW

This online activity targets healthcare gaps related to evidence-based recognition and prevention as well as timely treatment and management of age-related macular degeneration (AMD), impacting visual outcomes through guidelines and best practices, clinical trial data and strategies to facilitate earlier initiation of therapy.

  • By addressing these gaps, you can assess whether your approach to AMD management through utilization of current treatment guidelines, individualization of treatment approach and strategies for overcoming treatment barriers – could be modified to help close these gaps.
  • Expert discussion will guide you in analyzing and identifying appropriate candidates for anti-VEGF therapy, utilizing guidelines and clinical trial data on efficacy and safety to affect patient outcomes.
  • You will also be immersed in dynamic animations utilizing a virtual reality platform to memorably highlight key points related to anti-VEGF therapy in AMD and the recognition of retinal vasculitis.

TARGET AUDIENCE

This activity is designed to meet the educational needs of retina specialists, ophthalmologists, primary care providers, optometrists, and other healthcare providers who manage patients with age-related macular degeneration.

LEARNING OBJECTIVES

After completing the CME activity, learners should be better able to:

  • Incorporate consistent use of evidence-based screening and prevention strategies for patients at risk of AMD
  • Apply clinical trial data and guidelines to the selection of therapies for the treatment of patients with AMD
  • Identify barriers to early intervention and communicate to patients the importance for early initiation of therapy in AMD

ACCREDITATION STATEMENT: Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.

CREDIT DESIGNATION STATEMENT: Med Learning Group designates this online activity for a maximum of 1.0 AMA Category 1 creditTM. Physicians should claim only the credit commensurate with the extent of their participation in the live virtual activity.

NURSING CREDIT INFORMATION: Purpose: This program would be beneficial for nurses involved in the care of patients with AMD. Credits: 1.0 ANCC Contact Hour.

CNE Accreditation Statement:

Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG‐sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

SriniVas Sadda, MD discloses the following financial interests or relationships:

  • Research Instruments: Carl Zeiss Meditec, Centervue, Heidelberg, Nidek, Optos, Topcon
  • Consultant: Genentech, MacuLogix, Regeneron, Notal Vision

CME Content Review

The content of this activity was independently peer-reviewed. The reviewer of this activity has nothing to disclose.

CNE Content Review

The content of this activity was peer-reviewed by a nurse reviewer.

Teresa L. Keating, MSN, RN, WHNP
Ultimate Medical Academy/CCM – Lead Nurse Planner

The reviewer of this activity has nothing to disclose

Staff Planners and Managers

The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

  • Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to d
  • Christina Gallo, SVP, Educational Development of Med Learning Group, has nothing to
  • Chris Drury, Director of Medical and Scientific Services of Med Learning Group, has nothing to disclose.
  • Teresa L. Keating, MSN, RN, WHNP, UMA/CMM – LNP, has nothing to disclose.
  • Ana Maria Albino, Senior Program Manager of Med Learning Group, has nothing to
  • Amanda Jenkins, Program Coordinator of Med Learning Group, has nothing to disclose.
  • Brianna Hanson, MPH, Outcomes and Accreditation Coordinator of Med Learning Group, has nothing to disclose.
  • Lauren Welch, MA, VP, Accreditation and Outcomes of Med Learning Group, has nothing to

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During the course of this lecture, the faculty may mention the use of medications for both FDA‐approved and non‐approved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this online activity. To receive CME/CNE credit participants must:

  1. Read the CME/CNE information and faculty disclosures;
  2. Participate in the online activity; and
  3. Complete pre-and-post surveys and evaluations.

You will receive your certificate as a downloadable file.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision‐making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at [email protected]

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]

RELEASE DATE: October 01, 2021

EXPIRATION DATE: October 01, 2022

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy‐policy/

Copyright © 2021 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form other than personal use without the express written permission of Med Learning Group is prohibited.

View Activity

Jul
23
Thu
Seeing Clearer: Optimizing the Use of Vascular Endothelial Growth Factor Inhibitors in Age Related Macular Degeneration – VA Grand Rounds Enduring Activity
Jul 23 2020 @ 7:55 am – Jul 23 2022 @ 8:55 am

Seeing Clearer: Optimizing the Use of VEGF Inhibitors in
Age-related Macular Degeneration (AMD)

View Activity

PROGRAM CHAIR

David Brown, MD

Director of Research, Retina Consultants of Texas

Clinical Professor of Ophthalmology, Baylor College of Medicine

Dallas, TX

 

PROGRAM OVERVIEW

This online activity targets healthcare gaps correlated with screening, multidisciplinary care and timely intervention in age-macular degeneration (AMD), which can impact vision-related quality of life.

  • By addressing these gaps, you can assess whether your approach to AMD management through screening, utilization of clinical trial data to guide appropriate treatment and multidisciplinary coordination for comprehensive AMD management – could be modified to help both strategize treatment design and close these gaps.
  • Expert discussion will guide you in identifying appropriate opportunities for early intervention, as well as assessing impact that AMD can have on vision-related quality of life.
  • You will also be immersed in dynamic whiteboard animations to memorably highlight key points related to how the inflammatory and vascular endothelial growth factor (VEGF) pathways lead to the development of AMD, as well as the fundoscopic retinal changes associated with each stage of AMD.

 

TARGET AUDIENCE

This online CME activity is designed to meet the educational needs of retina specialists, ophthalmologists, primary care providers, optometrists, managed care providers, pharmacists and other healthcare providers who manage patients with age-related macular degeneration.

 

LEARNING OBJECTIVES

  • Communicate the importance of proper eye care and early intervention in preventing progressive visual changes in patients with or at risk for AMD
  • Incorporate collaborative strategies into clinical practice that promote team-based communication, maintain continuity of care, and improve treatment adherence for patients with or who are at risk for AMD
  • Identify pathogenic changes in AMD that would be best managed with a multidisciplinary approach
  • Evaluate clinical trial data on the efficacy and safety of currently available treatment options for the management of AMD

 

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.

 

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this online activity for a maximum of 1.0 AMA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the online activity.

NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the care of patients with AMD.

CNE Credits: 1.0 ANCC Contact Hour.

CNE ACCREDITATION STATEMENT

Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission of Accreditation. Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturers of any commercial products and/or providers of commercial services that are discussed in an educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Faculty Member Disclosures
David Brown, MD Consulting work for Adverum, Alexion, Annexon Biosciences, Apellis, Boehringer Ingelheim, Celltrion, Clearside Biomedical, Dark Horse Consulting, Horizon Therapeutics, Genentech, Kodiak, Laboratories THEA, Lineage (BioTime), Novartis, Ocular Theapeutix, OPTOS, Regeneron, Retinal Medical, Senju Pharmaceutical and Verseon.

Grant funding from Adverum, Aldeyra, Apellis, Bayer, BIRC, Boehringer Ingelheim, Clearside Biomedical, Cleveland Clinic Foundation, F. Hoffmann-La Roche Limited, Gyroscope, Ionis, Iveric, Kodiak, Lowy Medical Research Institute, Lumithera, Nanoscope, NEI/NIH, NGM, Novartis, OIRRC, OPTOS, Oxurion, Regeneron, REGENXBIO, SamChunDang Pharma, Santen, Senju Pharmaceutical

 

CME Content Review

The content of this activity was independently peer reviewed.

The reviewer of this activity has nothing to disclose.

CNE Content Review

The content of this activity was peer reviewed by a nurse reviewer.

The reviewer of this activity has nothing to disclose.

Staff Planners and Managers

The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

  • Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
  • Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
  • Nicole Longo, DO, FACOI, Director of Medical and Scientific Services for Med Learning Group has nothing to disclose.
  • Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
  • Marissa Mays-Verman, Program Manager for Med Learning Group, has nothing to disclose.
  • Brianna Hanson, MPH, Accreditation and Outcomes Coordinator, has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this online activity. To receive CME/CNE credit participants must:

  1. Read the CME/CNE information and faculty disclosures.
  2. Participate in the online activity.
  3. Complete the online post-test and evaluation.

You will receive your certificate as a downloadable file.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are science based.

This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at [email protected]

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]

 

Copyright © 2021 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.

Jul
24
Fri
Seeing Clearer: Optimizing the Use of Vascular Endothelial Growth Factor Inhibitors in Age-related Macular Degeneration Immersive Simulation Experience
Jul 24 2020 @ 1:00 am – Jul 24 2022 @ 2:00 am

Seeing Clearer: Optimizing the Use of Vascular Endothelial Growth Factor Inhibitors in Age-related Macular Degeneration
Immersive Simulation Experience

View Activity

FACULTY


Allen C. Ho, MD, FACS
Attending Surgeon and Director of Retina Research, Wills Eye Hospital
Professor of Ophthalmology, Thomas Jefferson University
Mid Atlantic Retina
Philadelphia, PA

PROGRAM OVERVIEW

The Age-related Macular Degeneration (AMD) Immersive Simulation Experience allows learners to engage in clinical decision-making targeting diagnosis and therapeutic approaches in AMD management. By participating in this simulated 3D encounter, you will observe patient-provider interactions and use pertinent information from the patients’ electronic chart to decide the next best course of action at various key points in care. Highlighted areas for this activity include assessment of AMD classification, risk factor modification, interventions based on AMD classification, as well as the recognition and management of treatment-related adverse events.


TARGET AUDIENCE

This activity is designed to meet the educational needs of retina specialists, ophthalmologists, primary care providers, optometrists, and other healthcare providers who manage patients with age-related macular degeneration.


LEARNING OBJECTIVES

  • Communicate the importance of proper eye care and early intervention in preventing progressive visual changes in patients with or at risk for AMD
  • Incorporate collaborative strategies into clinical practice that promote team-based communication, maintain continuity of care, and improve treatment adherence for patients with or who are at risk for AMD
  • Identify pathogenic changes in AMD that would be best managed with a multidisciplinary approach
  • Evaluate clinical trial data on the efficacy and safety of currently available treatment options for the management of AMD

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.


CREDIT DESIGNATION STATEMENT

Med Learning Group designates this online activity for a maximum of 1.0 AMA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the online activity.


NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the care of patients with age-related macular degeneration.
CNE Credits: 1.0 ANCC Contact Hour.


CNE ACCREDITATION STATEMENT

Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.


DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturers of any commercial products and/or providers of commercial services that are discussed in an educational activity.


DISCLOSURE OF CONFLICTS OF INTEREST

Dr. Allen Ho discloses the following:

  • He is a consultant/advisor for Adverum Biotechnologies, Aerie Pharmaceuticals, Alcon Laboratories, Aldeyra Therapeutics, Allergan, Apellis Pharmaceuticals, Applied Genetic Technologies Corporation (AGTC), AsclepiX Therapeutics, Beaver-Visitec International, BioTime, Chengdu Kanghong Biotechnology, Genentech, Graybug Vision, Gyroscope Therapeutics, IRIDEX, Iveric/Ophthotech, Johnson & Johnson, Lineage Cell Therapeutics/ BioTime, Notal Vision, ONL Therapeutics, Optovue, PanOptica, Regeneron Pharmaceuticals, and REGENXBIO
  • He has received grants from Aerie, AGTC, Alcon Laboratories, Aldeyra, Allergan, Apellis, BioTime, Chengdu Kanghong Biotechnology, Genentech, Gemini Medical, Graybug Vision, Gyroscope, Iveric/Ophthotech, Johnson & Johnson, Lineage/BioTime, LumiThera, National Eye Institute, Novartis, Optovue, ProQR Therapeutics, Regeneron Pharmaceuticals, REGENXBIO, and Sanofi
  • He has ownership in Covalent Medical, ONL Therapeutics, and PanOptica

CME Content Review
The content of this activity was independently peer-reviewed.
The reviewer of this activity has nothing to disclose.

CNE Content Review
The content of this activity was peer-reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.

Staff, Planners, and Managers
The staff, planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Matthew Frese, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development of Med Learning Group, has nothing to disclose.
Ana Maria Albino, Senior Program Manager of Med Learning Group, has nothing to disclose.
Nicole Longo, DO, FACOI, Director of Medical and Scientific Services of Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP of Accreditation and Outcomes of Med Learning Group, has nothing to disclose.
Brianna Hanson, Accreditation and Outcomes Coordinator of Med Learning Group, has nothing to disclose.


DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During this lecture, faculty may mention the use of medications for both FDA-approved and non-approved indications.


METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this online activity. To receive CME/CNE credit participants must:

  1. Read the CME/CNE information and faculty disclosures;
  2. Participate in the online activity; and
  3. Complete pre-and-post surveys and evaluation.

You will receive your certificate as a downloadable file.


DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are science-based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at [email protected].

RELEASE DATE: April 2, 2021

EXPIRATION DATE: April 2, 2022

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected].

 

Copyright © 2021 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.

Jun
21
Sun
Seeing Past the Treatment Horizon: Anti-VEGF Therapies and Beyond in Retinal Disease Track: Age-related Macular Degeneration (Optometry)
Jun 21 2020 @ 9:00 am – Oct 1 2022 @ 10:00 am

Seeing Past the Treatment Horizon: Anti-VEGF Therapies and Beyond in Retinal Disease Track: Age-related Macular Degeneration (Optometry)

View Activity

FACULTY

Steven Ferrucci, OD, FAAO
Chief of Optometry, Sepulveda VA Medical Center
Los Angeles, CA
Professor, Southern California College of Optometry at Marshall B. Ketchum University
Fullerton, CA

PROGRAM OVERVIEW

This online activity targets healthcare gaps related to evidence-based recognition and prevention as well as timely treatment and management of age-related macular degeneration (AMD), impacting visual outcomes through guidelines and best practices, clinical trial data and strategies to facilitate earlier initiation of therapy.

  • By addressing these gaps, you can assess whether your approach to AMD management through utilization of current treatment guidelines, individualization of treatment approach and strategies for overcoming treatment barriers – could be modified to help close these gaps.
  • Expert discussion will guide you in analyzing and identifying appropriate candidates for anti-VEGF therapy, utilizing guidelines and clinical trial data on efficacy and safety to affect patient outcomes.
  • You will also be immersed in dynamic animations utilizing a virtual reality platform to memorably highlight key points related to anti-VEGF therapy in AMD and the recognition of retinal vasculitis.

TARGET AUDIENCE

This activity is designed to meet the educational needs of retina specialists, ophthalmologists, primary care providers, optometrists, and other healthcare providers who manage patients with age-related macular degeneration.

LEARNING OBJECTIVES

After completing the CME activity, learners should be better able to:

  • Incorporate consistent use of evidence-based screening and prevention strategies for patients at risk of AMD
  • Apply clinical trial data and guidelines to the selection of therapies for the treatment of patients with AMD
  • Identify barriers to early intervention and communicate to patients the importance for early initiation of therapy in AMD

ACCREDITATION STATEMENT: Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.

CREDIT DESIGNATION STATEMENT: Med Learning Group designates this online activity for a maximum of 1.25 AMA Category 1 creditTM. Physicians should claim only the credit commensurate with the extent of their participation in the live virtual activity.

NURSING CREDIT INFORMATION: Purpose: This program would be beneficial for nurses involved in the care of patients with AMD. Credits: 1.25 ANCC Contact Hour.

CNE Accreditation Statement:

Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 1.25 contact hour of continuing nursing education of RNs and APNs.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG‐sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Steven Ferrucc, OD, FAAO discloses the following financial interests or relationships:

  • Consultant: Centervue, Science Based Health, Visible Genomics
  • Speakers’ Bureau: Genentech, MacuLogix, Regeneron, Notal Vision

CME Content Review

The content of this activity was independently peer-reviewed. The reviewer of this activity has nothing to disclose.

CNE Content Review

The content of this activity was peer-reviewed by a nurse reviewer.

Teresa L. Keating, MSN, RN, WHNP
Ultimate Medical Academy/CCM – Lead Nurse Planner

The reviewer of this activity has nothing to disclose

Staff Planners and Managers

The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

  • Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to d
  • Christina Gallo, SVP, Educational Development of Med Learning Group, has nothing to
  • Chris Drury, Director of Medical and Scientific Services of Med Learning Group, has nothing to disclose.
  • Teresa L. Keating, MSN, RN, WHNP, UMA/CMM – LNP, has nothing to disclose.
  • Ana Maria Albino, Senior Program Manager of Med Learning Group, has nothing to
  • Amanda Jenkins, Program Coordinator of Med Learning Group, has nothing to disclose.
  • Brianna Hanson, MPH, Outcomes and Accreditation Coordinator of Med Learning Group, has nothing to disclose.
  • Lauren Welch, MA, VP, Accreditation and Outcomes of Med Learning Group, has nothing to

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During the course of this lecture, the faculty may mention the use of medications for both FDA‐approved and non‐approved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this online activity. To receive CME/CNE credit participants must:

  1. Read the CME/CNE information and faculty disclosures;
  2. Participate in the online activity; and
  3. Complete pre-and-post surveys and evaluations.

You will receive your certificate as a downloadable file.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision‐making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at [email protected]

RELEASE DATE: October 01, 2021

EXPIRATION DATE: October 01, 2022

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy‐policy/

Copyright © 2021 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form other than personal use without the express written permission of Med Learning Group is prohibited.

View Activity

Jun
22
Mon
Seeing Past the Treatment Horizon: Anti-VEGF Therapies and Beyond in Retinal Disease Track: Age-related Macular Degeneration (Retina/Ophthalmology)
Jun 22 2020 @ 9:00 am – Oct 1 2022 @ 10:00 am

Seeing Past the Treatment Horizon: Anti-VEGF Therapies and Beyond in Retinal Disease Track: Age-related Macular Degeneration (Retina/Ophthalmology)

View Activity

FACULTY

SriniVas Sadda, MD
Professor of Ophthalmology
Doheny Eye Institute
David Geffen School of Medicine
University of California – Los Angeles

PROGRAM OVERVIEW

This online activity targets healthcare gaps related to evidence-based recognition and prevention as well as timely treatment and management of age-related macular degeneration (AMD), impacting visual outcomes through guidelines and best practices, clinical trial data and strategies to facilitate earlier initiation of therapy.

  • By addressing these gaps, you can assess whether your approach to AMD management through utilization of current treatment guidelines, individualization of treatment approach and strategies for overcoming treatment barriers – could be modified to help close these gaps.
  • Expert discussion will guide you in analyzing and identifying appropriate candidates for anti-VEGF therapy, utilizing guidelines and clinical trial data on efficacy and safety to affect patient outcomes.
  • You will also be immersed in dynamic animations utilizing a virtual reality platform to memorably highlight key points related to anti-VEGF therapy in AMD and the recognition of retinal vasculitis.

TARGET AUDIENCE

This activity is designed to meet the educational needs of retina specialists, ophthalmologists, primary care providers, optometrists, and other healthcare providers who manage patients with age-related macular degeneration.

LEARNING OBJECTIVES

After completing the CME activity, learners should be better able to:

  • Incorporate consistent use of evidence-based screening and prevention strategies for patients at risk of AMD
  • Apply clinical trial data and guidelines to the selection of therapies for the treatment of patients with AMD
  • Identify barriers to early intervention and communicate to patients the importance for early initiation of therapy in AMD

ACCREDITATION STATEMENT: Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.

CREDIT DESIGNATION STATEMENT: Med Learning Group designates this online activity for a maximum of 1.0 AMA Category 1 creditTM. Physicians should claim only the credit commensurate with the extent of their participation in the live virtual activity.

NURSING CREDIT INFORMATION: Purpose: This program would be beneficial for nurses involved in the care of patients with AMD. Credits: 1.0 ANCC Contact Hour.

CNE Accreditation Statement:

Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG‐sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

SriniVas Sadda, MD discloses the following financial interests or relationships:

  • Research Instruments: Carl Zeiss Meditec, Centervue, Heidelberg, Nidek, Optos, Topcon
  • Consultant: Genentech, MacuLogix, Regeneron, Notal Vision

CME Content Review

The content of this activity was independently peer-reviewed. The reviewer of this activity has nothing to disclose.

CNE Content Review

The content of this activity was peer-reviewed by a nurse reviewer.

Teresa L. Keating, MSN, RN, WHNP
Ultimate Medical Academy/CCM – Lead Nurse Planner

The reviewer of this activity has nothing to disclose

Staff Planners and Managers

The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

  • Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to d
  • Christina Gallo, SVP, Educational Development of Med Learning Group, has nothing to
  • Chris Drury, Director of Medical and Scientific Services of Med Learning Group, has nothing to disclose.
  • Teresa L. Keating, MSN, RN, WHNP, UMA/CMM – LNP, has nothing to disclose.
  • Ana Maria Albino, Senior Program Manager of Med Learning Group, has nothing to
  • Amanda Jenkins, Program Coordinator of Med Learning Group, has nothing to disclose.
  • Brianna Hanson, MPH, Outcomes and Accreditation Coordinator of Med Learning Group, has nothing to disclose.
  • Lauren Welch, MA, VP, Accreditation and Outcomes of Med Learning Group, has nothing to

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During the course of this lecture, the faculty may mention the use of medications for both FDA‐approved and non‐approved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this online activity. To receive CME/CNE credit participants must:

  1. Read the CME/CNE information and faculty disclosures;
  2. Participate in the online activity; and
  3. Complete pre-and-post surveys and evaluations.

You will receive your certificate as a downloadable file.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision‐making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at [email protected]

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]

RELEASE DATE: October 01, 2021

EXPIRATION DATE: October 01, 2022

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy‐policy/

Copyright © 2021 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form other than personal use without the express written permission of Med Learning Group is prohibited.

View Activity

Jul
23
Thu
Seeing Clearer: Optimizing the Use of Vascular Endothelial Growth Factor Inhibitors in Age Related Macular Degeneration – VA Grand Rounds Enduring Activity
Jul 23 2020 @ 7:55 am – Jul 23 2022 @ 8:55 am

Seeing Clearer: Optimizing the Use of VEGF Inhibitors in
Age-related Macular Degeneration (AMD)

View Activity

PROGRAM CHAIR

David Brown, MD

Director of Research, Retina Consultants of Texas

Clinical Professor of Ophthalmology, Baylor College of Medicine

Dallas, TX

 

PROGRAM OVERVIEW

This online activity targets healthcare gaps correlated with screening, multidisciplinary care and timely intervention in age-macular degeneration (AMD), which can impact vision-related quality of life.

  • By addressing these gaps, you can assess whether your approach to AMD management through screening, utilization of clinical trial data to guide appropriate treatment and multidisciplinary coordination for comprehensive AMD management – could be modified to help both strategize treatment design and close these gaps.
  • Expert discussion will guide you in identifying appropriate opportunities for early intervention, as well as assessing impact that AMD can have on vision-related quality of life.
  • You will also be immersed in dynamic whiteboard animations to memorably highlight key points related to how the inflammatory and vascular endothelial growth factor (VEGF) pathways lead to the development of AMD, as well as the fundoscopic retinal changes associated with each stage of AMD.

 

TARGET AUDIENCE

This online CME activity is designed to meet the educational needs of retina specialists, ophthalmologists, primary care providers, optometrists, managed care providers, pharmacists and other healthcare providers who manage patients with age-related macular degeneration.

 

LEARNING OBJECTIVES

  • Communicate the importance of proper eye care and early intervention in preventing progressive visual changes in patients with or at risk for AMD
  • Incorporate collaborative strategies into clinical practice that promote team-based communication, maintain continuity of care, and improve treatment adherence for patients with or who are at risk for AMD
  • Identify pathogenic changes in AMD that would be best managed with a multidisciplinary approach
  • Evaluate clinical trial data on the efficacy and safety of currently available treatment options for the management of AMD

 

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.

 

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this online activity for a maximum of 1.0 AMA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the online activity.

NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the care of patients with AMD.

CNE Credits: 1.0 ANCC Contact Hour.

CNE ACCREDITATION STATEMENT

Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission of Accreditation. Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturers of any commercial products and/or providers of commercial services that are discussed in an educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Faculty Member Disclosures
David Brown, MD Consulting work for Adverum, Alexion, Annexon Biosciences, Apellis, Boehringer Ingelheim, Celltrion, Clearside Biomedical, Dark Horse Consulting, Horizon Therapeutics, Genentech, Kodiak, Laboratories THEA, Lineage (BioTime), Novartis, Ocular Theapeutix, OPTOS, Regeneron, Retinal Medical, Senju Pharmaceutical and Verseon.

Grant funding from Adverum, Aldeyra, Apellis, Bayer, BIRC, Boehringer Ingelheim, Clearside Biomedical, Cleveland Clinic Foundation, F. Hoffmann-La Roche Limited, Gyroscope, Ionis, Iveric, Kodiak, Lowy Medical Research Institute, Lumithera, Nanoscope, NEI/NIH, NGM, Novartis, OIRRC, OPTOS, Oxurion, Regeneron, REGENXBIO, SamChunDang Pharma, Santen, Senju Pharmaceutical

 

CME Content Review

The content of this activity was independently peer reviewed.

The reviewer of this activity has nothing to disclose.

CNE Content Review

The content of this activity was peer reviewed by a nurse reviewer.

The reviewer of this activity has nothing to disclose.

Staff Planners and Managers

The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

  • Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
  • Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
  • Nicole Longo, DO, FACOI, Director of Medical and Scientific Services for Med Learning Group has nothing to disclose.
  • Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
  • Marissa Mays-Verman, Program Manager for Med Learning Group, has nothing to disclose.
  • Brianna Hanson, MPH, Accreditation and Outcomes Coordinator, has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this online activity. To receive CME/CNE credit participants must:

  1. Read the CME/CNE information and faculty disclosures.
  2. Participate in the online activity.
  3. Complete the online post-test and evaluation.

You will receive your certificate as a downloadable file.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are science based.

This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at [email protected]

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]

 

Copyright © 2021 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.

Jul
24
Fri
Seeing Clearer: Optimizing the Use of Vascular Endothelial Growth Factor Inhibitors in Age-related Macular Degeneration Immersive Simulation Experience
Jul 24 2020 @ 1:00 am – Jul 24 2022 @ 2:00 am

Seeing Clearer: Optimizing the Use of Vascular Endothelial Growth Factor Inhibitors in Age-related Macular Degeneration
Immersive Simulation Experience

View Activity

FACULTY


Allen C. Ho, MD, FACS
Attending Surgeon and Director of Retina Research, Wills Eye Hospital
Professor of Ophthalmology, Thomas Jefferson University
Mid Atlantic Retina
Philadelphia, PA

PROGRAM OVERVIEW

The Age-related Macular Degeneration (AMD) Immersive Simulation Experience allows learners to engage in clinical decision-making targeting diagnosis and therapeutic approaches in AMD management. By participating in this simulated 3D encounter, you will observe patient-provider interactions and use pertinent information from the patients’ electronic chart to decide the next best course of action at various key points in care. Highlighted areas for this activity include assessment of AMD classification, risk factor modification, interventions based on AMD classification, as well as the recognition and management of treatment-related adverse events.


TARGET AUDIENCE

This activity is designed to meet the educational needs of retina specialists, ophthalmologists, primary care providers, optometrists, and other healthcare providers who manage patients with age-related macular degeneration.


LEARNING OBJECTIVES

  • Communicate the importance of proper eye care and early intervention in preventing progressive visual changes in patients with or at risk for AMD
  • Incorporate collaborative strategies into clinical practice that promote team-based communication, maintain continuity of care, and improve treatment adherence for patients with or who are at risk for AMD
  • Identify pathogenic changes in AMD that would be best managed with a multidisciplinary approach
  • Evaluate clinical trial data on the efficacy and safety of currently available treatment options for the management of AMD

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.


CREDIT DESIGNATION STATEMENT

Med Learning Group designates this online activity for a maximum of 1.0 AMA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the online activity.


NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the care of patients with age-related macular degeneration.
CNE Credits: 1.0 ANCC Contact Hour.


CNE ACCREDITATION STATEMENT

Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.


DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturers of any commercial products and/or providers of commercial services that are discussed in an educational activity.


DISCLOSURE OF CONFLICTS OF INTEREST

Dr. Allen Ho discloses the following:

  • He is a consultant/advisor for Adverum Biotechnologies, Aerie Pharmaceuticals, Alcon Laboratories, Aldeyra Therapeutics, Allergan, Apellis Pharmaceuticals, Applied Genetic Technologies Corporation (AGTC), AsclepiX Therapeutics, Beaver-Visitec International, BioTime, Chengdu Kanghong Biotechnology, Genentech, Graybug Vision, Gyroscope Therapeutics, IRIDEX, Iveric/Ophthotech, Johnson & Johnson, Lineage Cell Therapeutics/ BioTime, Notal Vision, ONL Therapeutics, Optovue, PanOptica, Regeneron Pharmaceuticals, and REGENXBIO
  • He has received grants from Aerie, AGTC, Alcon Laboratories, Aldeyra, Allergan, Apellis, BioTime, Chengdu Kanghong Biotechnology, Genentech, Gemini Medical, Graybug Vision, Gyroscope, Iveric/Ophthotech, Johnson & Johnson, Lineage/BioTime, LumiThera, National Eye Institute, Novartis, Optovue, ProQR Therapeutics, Regeneron Pharmaceuticals, REGENXBIO, and Sanofi
  • He has ownership in Covalent Medical, ONL Therapeutics, and PanOptica

CME Content Review
The content of this activity was independently peer-reviewed.
The reviewer of this activity has nothing to disclose.

CNE Content Review
The content of this activity was peer-reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.

Staff, Planners, and Managers
The staff, planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Matthew Frese, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development of Med Learning Group, has nothing to disclose.
Ana Maria Albino, Senior Program Manager of Med Learning Group, has nothing to disclose.
Nicole Longo, DO, FACOI, Director of Medical and Scientific Services of Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP of Accreditation and Outcomes of Med Learning Group, has nothing to disclose.
Brianna Hanson, Accreditation and Outcomes Coordinator of Med Learning Group, has nothing to disclose.


DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During this lecture, faculty may mention the use of medications for both FDA-approved and non-approved indications.


METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this online activity. To receive CME/CNE credit participants must:

  1. Read the CME/CNE information and faculty disclosures;
  2. Participate in the online activity; and
  3. Complete pre-and-post surveys and evaluation.

You will receive your certificate as a downloadable file.


DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are science-based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at [email protected].

RELEASE DATE: April 2, 2021

EXPIRATION DATE: April 2, 2022

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected].

 

Copyright © 2021 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.

Accreditation Statement
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Menu

Search

Clinician Scientific & Educational Resources

The RELIEF Clinical Toolkit is an online tool that aims to provide clinicians with up-to-date information on the presentation, prognosis, pathophysiology, and treatment strategies for age-related macular degeneration (AMD). Click on one of the options below to learn more about AMD.

This activity is provided by Med Learning Group. This activity is co-provided by Ultimate Medical Academy/Complete Conference Management (CCM). This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.

Copyright © 2019 | AMD Relief | All Rights Reserved | Website by Divigner

Scientific Council

Neil M. Bressler, MD

James P. Gills Professor of Ophthalmology
Professor of Ophthalmology, Johns Hopkins University School of Medicine
Wilmer Eye Institute, Johns Hopkins Medicine
Baltimore, MD

A. Paul Chous, MA, OD, FAAO

Specializing in Diabetes Eye Care & Education, Chous Eye Care Associates
Adjunct Professor of Optometry, Western University of Health Sciences
AOA Representative, National Diabetes Education Program
Tacoma, WA

Steven Ferrucci, OD, FAAO

Chief of Optometry, Sepulveda VA Medical Center
Professor, Southern California College of Optometry at Marshall B. Ketchum University
Sepulveda, CA

Julia A. Haller, MD

Ophthalmologist-in-Chief
Wills Eye Hospital
Philadelphia, PA

Allen C. Ho, MD, FACS

Director, Retina Research
Wills Eye Hospital
Professor and Chair of the Department of Ophthalmology
Thomas Jefferson University Hospitals
Philadelphia, PA

Charles C. Wykoff, MD, PhD

Director of Research, Retina Consultants of Houston
Associate Professor of Clinical Ophthalmology
Blanton Eye Institute & Houston Methodist Hospital
Houston, TX